Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma
暂无分享,去创建一个
C. Ohyama | S. Hatakeyama | T. Narita | T. Yoneyama | N. Fujita | H. Yamamoto | Y. Hashimoto | H. Iwamura | T. Yoneyama | T. Okamoto | T. Hamaya | K. Togashi
[1] L. Pickering,et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer , 2022, The Lancet.
[2] A. Reiner-Benaim,et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer , 2021, Annals of Oncology.
[3] R. Grifantini,et al. Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment , 2021, European Journal of Cancer.
[4] L. Kadouri,et al. Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment. , 2021, JAMA oncology.
[5] A. Iafrate,et al. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Robin L. Jones,et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.
[7] G. Ohji,et al. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer , 2021, Journal of Infection and Chemotherapy.
[8] D. Wolf,et al. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment , 2021, ESMO Open.
[9] H. Nishiyama,et al. Impact of the objective response to and number of cycles of platinum‐based first‐line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab , 2021, International journal of urology : official journal of the Japanese Urological Association.
[10] H. Nishiyama,et al. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. , 2021, Urologic oncology.
[11] H. Nishiyama,et al. Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era , 2021, Cancer medicine.
[12] S. Fafi-Kremer,et al. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. , 2021, JAMA.
[13] K. Ivens,et al. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients , 2021, Kidney360.
[14] H. Nishiyama,et al. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR , 2021, Cancer Immunology, Immunotherapy.
[15] H. Nishiyama,et al. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. , 2021, Journal of geriatric oncology.
[16] H. Nishiyama,et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era , 2021, International Journal of Clinical Oncology.
[17] J. Achard,et al. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients , 2021, Journal of the American Society of Nephrology : JASN.
[18] I. Étienne,et al. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients , 2021, Journal of the American Society of Nephrology : JASN.
[19] T. Tsuzuki,et al. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis , 2021, BJU international.
[20] K. Pradhan,et al. Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.
[21] N. Moskovits,et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer , 2021, JAMA oncology.
[22] S. Boyd,et al. Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis , 2021, medRxiv.
[23] H. Nishiyama,et al. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort , 2021, Cancer medicine.
[24] E. Chamorey,et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors , 2021, Annals of Oncology.
[25] A. Kribben,et al. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) , 2021, Viruses.
[26] L. Poon,et al. Neutralizing antibody titres in SARS-CoV-2 infections , 2021, Nature communications.
[27] N. Berger,et al. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. , 2020, JAMA oncology.
[28] H. Nishiyama,et al. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab , 2020, Cancer science.
[29] T. Habuchi,et al. Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study , 2020, International journal of urology : official journal of the Japanese Urological Association.
[30] H. Haslacher,et al. Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity , 2020, medRxiv.
[31] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[32] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[33] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.